At a glance
ClinicalIndex Comparison RecordPhase 4Completed· 191 enrolled
Drug / intervention
montelukast sodium +1 moredrug
Likely dose
montelukast sodium 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Korean Study of "Real-World" Montelukast Use in Mild Asthmatic Children With Concomitant Allergic Rhinitis
In Brief
A Phase 4 clinical trial evaluating montelukast sodium and inhaled corticosteroid for Asthma and Allergic Rhinitis. Completed, enrolled 191 participants.
Detailed Summary
The purpose of this study is to assess real-world effectiveness of montelukast in children (2 to 14 years) with asthma and allergic rhinitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAsthma, Allergic Rhinitis
Countries--
Collaborators--
Timeline
Phase 4CompletedFinished
20052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
Enrollment StartJan 2005
First PostedMar 2007
Primary CompletionOct 2007
TodayJul 2026
First PostedMar 2, 2007
Enrollment StartJan 1, 2005
Primary CompletionOct 1, 2007
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 19.3 years ago
Interventions
montelukast sodiumdrug
Montelukast 4/5 mg tablet (oral chewable), once daily, 12 weeks to up to 12 months
inhaled corticosteroiddrug
Inhaled corticosteroid solution, 1-4 puffs daily, 12 weeks to up to 12 months